BACKGROUND: Exchange transfusion is a mainstay in the treatment of sickle cell anemia. Transfusion recipients with sickle cell disease (SCD) can be transfused over 10 units per therapy, an intervention that replaces circulating sickle red blood cells (RBCs) with donor RBCs. Storage of RBCs makes the intervention logistically feasible. The average storage duration for units transfused at the Duke University Medical Center is approximately 2 weeks, a time window that should anticipate the accumulation of irreversible storage lesion to the RBCs. However, no metabolomics study has been performed to date to investigate the impact of exchange transfusion on recipients' plasma and RBC phenotypes.
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STUDY DESIGN AND METHODS: Plasma and RBCs
were collected from patients with sickle cell anemia before transfusion and within 5 hours after exchange transfusion with up to 11 units, prior to metabolomics analyses.
RESULTS:
Exchange transfusion significantly decreased plasma levels of markers of systemic hypoxemia like lactate, succinate, sphingosine 1-phosphate, and 2-hydroxyglutarate. These metabolites accumulated in transfused RBCs, suggesting that RBCs may act as scavenger/reservoirs. Transfused RBCs displayed higher glycolysis, total adenylate pools, and 2,3-diphosphoglycerate, consistent with increased capacity to deliver oxygen. Plasma levels of acylcarnitines and amino acids decreased, while fatty acids and potentially harmful phthalates increased upon exchange transfusion.
CONCLUSION:
Metabolic phenotypes confirm the benefits of the transfusion therapy in transfusion recipients with SCD and the reversibility of some of the metabolic storage lesion upon transfusion in vivo in 2-week-old RBCs. However, results also suggest that potentially harmful plasticizers are transfused. S ickle cell disease (SCD) is a monogenic hemoglobinopathy characterized by a point mutation in the β-globin gene. This mutation results from a single nucleotide substitution (GAG to GTG) in the codon coding for Amino Acid 6 (glutamate à valine). Hemoglobin tetramers containing mutant β-globin chains tend to polymerize at the membrane, forming the so-called sickle hemoglobin.
While morbidity and mortality are significant in this population, patients demonstrate substantial phenotypic heterogeneity even in the presence of identical mutant alleles of the β-globin gene, 1 which could be in part explained by underlying genotypic confounders, such as glucose 6-phosphate dehydrogenase deficiency. 2 SCD is characterized by persistent episodes of hemolytic anemia and the occurrence of acute vaso-occlusive crises when the sickling red blood cells (RBCs) clog the fine capillary beds. 3 The cumulative impact of recurring vaso-occlusive crises progressively damages many organs, including the kidneys, lungs, and brain. Importantly, children and adults with SCD have a high prevalence (4%) of cerebrovascular accidents 4 and an alarmingly high rate ABBREVIATIONS: ADP = adenosine diphosphate; AMP = adenosine monophosphate; ATP = adenosine triphosphate; DPG = 2,3-diphosphoglycerate; PPP = pentose phosphate pathway; SCD = sickle cell disease.
(approx. 50%) of recurrence within 2 years without therapeutic intervention. 5 The use of RBC transfusions or performing exchange transfusions can significantly reduce the risk of overt stroke and recurrent stroke 6 but can be associated with both acute and chronic complications, including iron overload, iron-mediated hypercoagulability, or development of alloimmunization over time. 7, 8 Indeed, transfusion of more than 10 units of RBCs (with an approximate total volume of >4.5 L) is logistically constrained by the availability of fresh units to be transfused, which implies that such units should be stored under blood bank conditions. However, as RBCs are stored in the blood bank, they accumulate a series of biochemical and morphological alterations, collectively referred to as the storage lesion. 9 The stored RBCs are challenged by low storage temperatures, 10 incubation with nonbiological media (i.e., storage additives [11] [12] [13] ), and exposure to (mM levels of ) plasticizers, 14 Cr-labeled posttransfusion recovery studies in healthy human volunteers, 30 an assay that provides information on the RBCs' ability to circulate but not necessarily their ability to deliver oxygen. Storage-induced loss of potency may negatively impact massively transfused recipients, such as trauma patients. 29 Similar considerations can be made for massively and chronically transfused SCD recipients undergoing lifelong transfusion therapy, where the opportunity to space out in time the frequency of transfusion therapies administered per year holds evident beneficial implications for the quality of life of the recipient as well as for the economic burden to the health care system. Therefore, transfusion to pediatric patients with SCD often privileges fresher units (e.g., the average age of units transfused to recipients with SCD at Duke is 15 days
31
). This time window anticipates the threshold for irreversible storage lesion(s) to key proteins and enzymes relevant to RBC function, energy, and redox homeostasis, such as hemoglobin/band 3, glyceraldehyde 3-phosphate dehydrogenase, and peroxiredoxin-2, respectively. 18, 19, 21, 32 Over the past few years, several studies have leveraged the power of omics technologies to investigate the impact of SCD on RBC biology, especially with respect to SCD-specific adaptations at the protein 33 and metabolic level. [34] [35] [36] [37] 
MATERIALS AND METHODS

Patient population
Blood samples were collected from transfusion recipients with SCD prior to or 5 hours after exchange transfusion (eight exchange transfusion treatments; min = 3:37; max = 6:01; Fig. 1A ), upon receiving written informed consent and in conformity with the Declaration of Helsinki under protocol approved by the Duke University Medical Center (no. NCT02731157). All patients were primarily sickle cell type SS, in their baseline state of health, and receiving chronic exchange transfusions for stroke prophylaxis. None of the patients had acute illness during the 2 weeks prior to or during the exchange transfusion. Patients with stable chronic exchange protocols (as defined with consistent intervals between exchange) were enrolled. Only adult patients were enrolled to further minimize age-related differences. Although hydroxyurea is the standard of care for patients to prevent complications, this therapy is not standard of practice for patients undergoing exchange transfusions. Therefore, none of the patients enrolled in this study were receiving hydroxyurea therapy. All patients were either at risk for stroke (based on elevated transcranial Doppler velocities) or had a history of stroke and were therefore at high risk for additional complications. Commercial reagents were purchased from SigmaAldrich unless otherwise noted. Plasma and RBCs were separated by centrifugation at 2500 × g for 10 minutes at 4 C.
Sample processing and metabolite extraction
A volume of 50 μL of RBCs and 20 μL of plasma was extracted in 450 and 980 μL, respectively, of lysis buffer (methanol:acetonitrile:water 5:3:2), before ice cold extraction by vortexing for 30 minutes at 4 C. 38, 39 Insoluble proteins were pelleted by centrifugation (10 minutes at 4 C and 10,000 × g), and supernatants were collected and stored at −80 C until analysis.
Ultra-high-performance liquid chromatography-mass spectrometry metabolomics
Analyses were performed using a Vanquish ultra-highperformance liquid chromatography system coupled online to a Q Exactive mass spectrometer (Thermo Fisher). Samples were resolved over a Kinetex C18 column (2.1 × 150 mm, 1.7 μm; Phenomenex) at 25 C using a 3-minute isocratic condition of 5% acetonitrile, 95% water, and 0.1% formic acid flowing at 250 μL/min, 40 or using a 9-minute gradient at 400 μL/min from 5-95% B (A: water/0.1% formic acid; B: acetonitrile/0.1% formic acid). 39 Mass spectrometry analysis and data elaboration were performed as described. 39 Metabolite assignments were performed using an open-source crossplatform metabolomics data analyzer (MAVEN, Princeton University), as described. 40 Graphs and statistical analyses (t test) were prepared with computer software (GraphPad Prism 5.0, GraphPad Software, Inc.) and principal component analyses were performed using metabolomics data analysis and interpretation software (Metaboanalyst 3.0, Wishart Research Group). 41 
RESULTS
Exchange transfusion significantly impacts the metabolic phenotypes of RBCs and plasma in SCD patients
Metabolomics analyses were performed via ultra-highperformance liquid chromatography-mass spectrometry in RBCs and plasma from eight patients with SCD prior to or 5 hours after the beginning of exchange transfusion therapies (Fig. 1A) . Each patient received up to 11 units of blood. The average storage duration of the transfused units was 16 AE 6 days. Information on pre-and postexchange transfusion hematologic parameters, including hemoglobin concentration, hematocrit, mean cell volume, mean cell hemoglobin, mean corpuscular hemoglobin concentrations, and RBC counts are provided in Table S1 (available as supporting information in the online version of this paper). A detailed report for 160 metabolites is provided in Table S1 , including compound names, KEGG IDs, metabolite mass to charge ratios (m/z), chromatographic retention times, and the polarity in which each metabolite was detected. Results indicate significant impacts on RBC and plasma metabolic phenotypes following exchange transfusion, as gleaned by partially supervised statistical analysis (PLS-DA in Pathway analyses revealed that transfused RBCs were characterized by higher glycolytic activity, which resulted in significantly lower levels of RBC glucose and higher levels of all glycolytic intermediates, including fructose bisphosphate, glyceraldehyde 3-phosphate, diphosphoglycerate, phosphoenolpyruvate, pyruvate, and lactate (Fig. 3A) . Increased glycolytic intermediates in RBCs upon exchange transfusion were also accompanied by significantly higher levels of highenergy phosphate compounds adenosine tri-and diphosphate (ATP and ADP), lower levels of low-energy adenosine monophosphate (AMP), and increases in RBC adenosine, an observation with overall improved preservation of the total adenylate pool in transfused RBCs in comparison to pretransfusion SCD RBCs (Fig. 3B) . Increased RBC levels of highenergy S-adenosyl-methionine, monophosphate, and phosphocreatine upon exchange transfusion are consistent with this observation (Fig. S3 , available as supporting information in the online version of this paper).
Transfused RBCs were also characterized by lower levels of early pentose phosphate pathway (PPP) oxidative phase intermediates (6-phosphogluconolactone) and increased levels of PPP by-products, ribose phosphate (and isobaric isomers), and sedoheptulose phosphate (Fig. 3C) . In the absence of in vivo tracing data to reveal metabolic fluxes, steady-state observations could be suggestive of increased PPP activation to cope with exacerbated oxidative stress upon transfusion. Decreased reduced and oxidized glutathione and 5-oxoproline (a by-product of the gamma-glutamyl cycle; Fig. 3D ) are suggestive of an overall decrease in the total glutathione pool and potentially indicate that transfused RBCs appear to be characterized by higher-energy metabolism in exchange for a decreased antioxidant metabolic capacity. However, these results are in part explained by decreased levels of dehydroascorbate (oxidized vitamin C; Fig. S3 ), which is converted to its reduced form through consumption of reduced glutathione.
Exchange transfusion impacts plasma metabolic phenotypes by increasing circulating levels of fatty acids and other metabolites that accumulate over storage in the RBCs transfused Significant alterations were observed in the plasma metabolic phenotypes of transfused SCD patients (Figs. 4 and S2) . Since exchange transfusion therapies are administered to counteract systemic hypoxemia, the observed decreases in systemic markers of hypoxia such as lactate, sphingosine 1-phosphate, succinate, and 2-hydroxyglutarate were expected (Fig. 4) . Decreases in oxidative stress (dehydroascorbate, hypoxanthine) and hemolysis markers (bilirubin, biliverdin; plasma ATP, ADP, and AMP) were noted upon exchange transfusion (Figs. 5 and S2). Unexpectedly, exchange transfusion significantly decreased the circulating levels of fatty acyl-conjugated carnitines (including hexanoyl, octanoyl, decanoyl, decenoyl, dodecanoyl, dodecenoyl, tetradecenoyl, and palmitoyl carnitines) and amino acids (including valine, leucine, isoleucine, proline, tyrosine, glycine, serine, glutamine, arginine, asparagine, and methionine; Figs. 4 and S2) . On the other hand, postexchange plasma was characterized by increases in free fatty acids, including arachidonic acid, docosahexaenoic acid, and docosapentaenoic acid (Fig. 5) , all metabolites that increase in stored RBC supernatants during storage in the blood bank. 9 Finally, phthalate plasticizers (phthalate, monoethylhexyl-phthalate, and di-ethylhexylphthalate), which leak from the bag during storage in the blood bank up to mM levels, are significantly increased in posttransfusion plasma of transfusion recipients with SCD (Fig. 5 ).
DISCUSSION
Here, we provided the first metabolic characterization of plasma and RBCs from patients with SCD prior to or after exchange transfusion. The results are novel in that they confirm that-despite the well-established storage-induced depletion of DPG within the first 2 weeks of storage 15, 42, 43 -RBCs stored for approximately 2 weeks are still capable of regenerating high- energy phosphate compounds ATP and DPG within 5 hours of transfusion to levels above those measured in patients' own sickle RBCs before transfusion. This observation is consistent with historical observations on the in vivo reversibility of some of the metabolic lesions for RBCs stored, 44 though the rate at which this phenomenon occurs may be influenced by the storage-dependent percentage of reversible/irreversible lesions to key glycolytic enzymes such as glyceraldehyde 3-phosphate dehydrogenase. However, in the present study, the absence of longitudinal samples after transfusion limits any sort of speculation with respect to kinetics for the observed phenomenon. Transfused RBCs in this study were more metabolically active, as inferred from lower steady-state levels of glucose and higher levels of all glycolytic intermediates and by-products in comparison to pretransfusion sickle RBCs, which are already characterized by supraphysiological glycolytic fluxes, as reported in other studies where stable isotope-labeled tracers were used. 37 RBC ATP, DPG, and sphingosine 1-phosphate were higher in transfused RBCs than in pretransfusion sickle RBCs. These metabolites play a key physiological role in stabilizing the tense deoxygenated state of hemoglobin and promoting oxygen offloading, 45 which would in turn counteract systemic hypoxemia. Consistently, exchange transfusion resulted in decreases in circulating levels of systemic markers of hypoxia such as lactate, sphingosine 1-phosphate, hypoxanthine, 46 2-hydroxyglutarate, 47 and succinate, all decreasing in postexchange transfusion plasma and increasing in posttransfusion RBCs that could function as a reservoir for these compounds. Therefore, our data clearly indicate that exchange transfusion was effective in restoring systemic tissue oxygenation in SCD recipients. In addition, these observations are interesting in the light of the recently appreciated role of succinate 48 and sphingosine 1-phosphate in mediating inflammatory sequelae and oxygen off-loading 45 in response to pathological systemic hypoxemia, such as in the case of trauma/hemorrhagic shock 49 and ischemia. 50 Plasma levels of succinate (and other carboxylic acids such as 2-hydroxyglutarate) have long been associated with hypoxic responses, in that they prevent the degradation of the hypoxia-inducible factor 1-α by inhibiting its hydroxylation by prolyl hydroxylases. 51 By regulating the activities of transcriptional activators TET enzymes (α-ketoglutaratedependent dioxygenase that hydroxylate methylcytosines in DNA), succinate (and fumarate) regulate the expression of hypoxia-inducible genes. 52 Circulating levels of carboxylic acids like succinate derive from decreased oxygen availability, which limits electron flow through the electron transport chain in mitochondria and results in electron transport chain uncoupling and accumulation of dicarboxylates. 53, 54 In patients with SCD, this may occur in mitochondriaendowed cells, such as endothelial cells or reticulocytes (since patients with SCD have high reticulocyte counts) or abnormal mature RBCs, which have been reported to contain residual mitochondria in patients with SCD. 55 Plasma levels of succinate in patients with SCD may thus trigger inflammatory responses through cell-autonomous mechanisms, though activation of the succinate receptor GPR91 has also been associated with late termination of inflammatory processes via noncell autonomous mechanisms. 56 Decreases of plasma dicarboxylates in transfusion recipients with SCD upon exchange transfusion may thus contribute to the beneficial impact of such therapy in mitigating not just systemic hypoxemia but also inflammatory complications in recipients with SCD. While sphingosine 1-phosphate is generated by RBCs sphingosine kinase 1 in response to hypoxia under physiological conditions (e.g., high-altitude hypoxia), 45 the same metabolite holds relevant physiological implications in patients with SCD, where it induces sickling by promoting the translocation to the membrane of sickle hemoglobin and its polymerization. 37, 57 Therefore, by decreasing circulating levels of sphingosine 1-phosphate, exchange transfusion contributes to mitigating sickling of the recipient's own RBCs. Of note, the overall antioxidant capacity of transfused RBCs in comparison to pretransfusion SCD is decreased, suggestive of 1) compensatory mechanisms in the sickle RBC to mitigate oxidative injury and/or 2) a long-lasting impact of storage-induced decrease in the total glutathione pool 11, 39, 58 that persists within 5 hours from the start of exchange transfusion. However, posttransfusion RBCs were characterized by higher steady-state levels of nonoxidative phase PPP metabolites (ribose phosphate and sedoheptulose phosphate), suggestive of an improved capacity to activate nicotinamide adenine dinucleotide phosphategenerating redox pathways in the transfused cells. Moreover, a beneficial impact of exchange transfusion was immediately evident with respect to decreased levels of circulating markers of hemolysis and oxidative stress, including extracellular ATP, ADP, AMP, and biliverdin/bilirubin. Exchange transfusion also results in significant dilution of circulating levels of amino acids, which are included in current storage additive formulations. Though future studies will have to investigate the functional implications of this observation, it is interesting to speculate that amino acids such as glutamine, glutamate, and arginine play a key role in redox and nitric oxide homeostasis. Therefore, posttransfusion plasma may not adequately sustain the metabolic demands of circulating cells/organs within the first few hours after transfusion unless novel amino acid-rich additives are introduced, or amino acids are supplemented in transfused recipients, either orally, intravenously, or, in trauma patients, enterally (though reviews of clinical data highlight some controversies 59 ). Plasma levels of circulating fatty acids, which are known to accumulate in stored RBC units as a function of storage age, 39, 43, 60 increased upon exchange transfusion in comparison to pretransfusion levels, while plasma levels of acyl-carnitines decreased. Normalization of circulating levels of acyl-carnitines by exchange transfusion may hold significant implications with respect to bleeding phenotypes of transfusion recipients in the light of the anticoagulant effect of this class of compounds. 61, 62 Despite the many beneficial effects of exchange transfusion highlighted above, plasticizers leaking from the storage bags were found to significantly accumulate in the plasma of transfused recipients with SCD. It is interesting to note that chronic exposure to plasticizers has been previously associated with prostate cancer and fertility issues in males 63 and reproductive outcomes in females in laboratory studies. 64, 65 Because phthalate plasticizers progressively accumulate in storage units as a function of storage time up to mM levels, 14 it is interesting to note that exchange transfusion would theoretically result in hundred-μM to low-mM levels of phthalate plasticizers in plasma and, in a population exposed chronically to transfusion such as patients with SCD, could promote untoward consequences beyond factors such as mortality, as tested in recent randomized clinical trials on the age of blood. It will be relevant to understand whether the age of blood, while not significantly associated with increased mortality in transfusion recipients as the recent randomized clinical trials suggest, may indeed be negatively associated with other morbidities in chronically exposed populations such as transfusion recipients with SCD. Whether clinical evidence of the aforementioned risks will be produced, the introduction of phthalate-free storage bags or alternative plasticizers with reduced toxicity may represent a readily available solution.
In the present study exchange transfusion was performed by administering only relatively fresh units (approx. 16 days old). In the light of reassuring evidence from randomized clinical trials, ethical concerns may now be mitigated and pave the way for future studies investigating whether similar phenotypes to those reported here would be observed in response to exchange transfusion with exclusively end-of-storage units. Finally, by impacting RBC hemolytic propensity, other factors such as donor sex, age, ethnicity, or donation frequency 26 may impact the transfusion efficacy and the metabolic phenotypes of transfused recipients, though the limited numbers of cases tested in the present study and the large number of units received from donors with different (and unknown) biology during the exchange transfusion therapy prevent us from drawing any reliable conclusion on these variables.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article. Fig. S1 . Hierarchical clustering analysis of RBC metabolic phenotypes in patients with SCD prior to and after exchange transfusion. Fig. S2 . Hierarchical clustering analysis of plasma metabolic phenotypes in patients with SCD prior to and after exchange transfusion. Fig. S3 . Additional significant metabolic changes in RBCs from patients with SCD prior to and after exchange transfusion (red, left; green, right, respectively). Table S1 . Metabolomics Report for plasma and RBCs.
